AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11829701 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 1024)
Number of subjects: 2064
Study 10350964 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified therapeutic community (TC) intervention
Number of subjects: 0
Study 10350964 — intervention group
Group type: COMPARATOR
Intervention: Standard services (treatment-as-usual, TAU)
Number of subjects: 0
Study 7872877 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on age and CNS score
Number of subjects: 300
Study 7872877 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set
Number of subjects: 300
Study 7872877 — intervention group
Group type: EXPERIMENTAL
Intervention: Test set
Number of subjects: 300
Study 2299802 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human Erythropoietin (rhEPO) 50 U/kg body wt
Number of subjects: 20
Study 2299802 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human Erythropoietin (rhEPO) 80 U/kg body wt
Number of subjects: 20
Study 7287240 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 37
Study 7287240 — intervention group
Group type: COMPARATOR
Intervention: 250 mg methyldopa (or 500 mg if poor response)
Number of subjects: 37
Study 31648455 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic mixture of morphine, ropivacaine, epinephrine, ketorolac and betamethasone
Number of subjects: 70
Study 31648455 — intervention group
Group type: COMPARATOR
Intervention: Same volume of mixture without betamethasone
Number of subjects: 70
Study 27720602 — intervention group
Group type: EXPERIMENTAL
Intervention: epinastine 0.05% ophthalmic solution
Number of subjects: 10
Study 27720602 — intervention group
Group type: COMPARATOR
Intervention: artificial tear fluid (control)
Number of subjects: 10
Study 26484902 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent variable delta
Number of subjects: 525
Study 26484902 — intervention group
Group type: COMPARATOR
Intervention: Established cognitive and functional scales
Number of subjects: 525
Study 26484902 — intervention group
Group type: COMPARATOR
Intervention: Homologs of delta based on reduced test batteries
Number of subjects: 525
Study 25093912 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU of vitamin D(3) for 9 months
Number of subjects: 314
Study 25093912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 22963378 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (in- and outpatient) including strength, flexibility, and aerobic exercise, performed 5 times/week during hospitalization and a combination of supervised and home-based sessions using the Wii device for 10 weeks after discharge.
Number of subjects: 24
Study 22963378 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol without any specific exercise program (Control group).
Number of subjects: 24
Study 18814016 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 60
Study 18814016 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 17294302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Trainer
Number of subjects: 30
Study 17294302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Trainer
Number of subjects: 30
Study 17294302 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 30
Study 15305311 — intervention group
Group type: EXPERIMENTAL
Intervention: GBE-GBE (continuation group)
Number of subjects: 1570
Study 15305311 — intervention group
Group type: EXPERIMENTAL
Intervention: GBE-NT (discontinuation group)
Number of subjects: 1570
Study 15305311 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-GBE (new treatment group)
Number of subjects: 1570
Study 15305311 — intervention group
Group type: COMPARATOR
Intervention: NT-NT (no treatment group)
Number of subjects: 1570
Study 11584476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer (IP)
Number of subjects: 219
Study 11584476 — intervention group
Group type: COMPARATOR
Intervention: No intercessory prayer (no IP)
Number of subjects: 219
Study 9512274 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated, self-expanding metal stents
Number of subjects: 75
Study 9512274 — intervention group
Group type: COMPARATOR
Intervention: Latex prostheses
Number of subjects: 75
Study 9512274 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior radiation and/or chemotherapy
Number of subjects: 75
Study 8062521 — intervention group
Group type: EXPERIMENTAL
Intervention: rapeseed oil mayonnaise with a small dose of sitostanol ester (800 mg/day of sitostanol)
Number of subjects: 15
Study 8062521 — intervention group
Group type: EXPERIMENTAL
Intervention: rapeseed oil mayonnaise with a higher dose of sitostanol ester (2000 mg/day of sitostanol)
Number of subjects: 15
Study 8062521 — intervention group
Group type: COMPARATOR
Intervention: rapeseed oil mayonnaise alone (control group)
Number of subjects: 15
Study 3173998 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU/cc heparin infusion
Number of subjects: 73
Study 3173998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 73
Study 3173998 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU/cc heparin infusion
Number of subjects: 73
Study 3173998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 73
Study 29325660 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 174
Study 29325660 — intervention group
Group type: COMPARATOR
Intervention: Standard of care WIC Loving Support BFPC program (Control)
Number of subjects: 174
Study 27575538 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Balloon Ablation (TBA)
Number of subjects: 40
Study 27575538 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Hysterectomy
Number of subjects: 40
Study 24587338 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting accuracy of dietary intake
Number of subjects: 161
Study 24587338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy reporters classification
Number of subjects: 161
Study 22512264 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin + Metformin
Number of subjects: 171
Study 22512264 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Metformin
Number of subjects: 171
Study 20810376 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (up to 12 home or telephone contacts over 4 months)
Number of subjects: 237
Study 20810376 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 telephone calls and educational materials)
Number of subjects: 237
Study 18172697 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) added to general practitioners' care
Number of subjects: 135
Study 18172697 — intervention group
Group type: COMPARATOR
Intervention: General practitioners' care only
Number of subjects: 135
Study 15669610 — intervention group
Group type: EXPERIMENTAL
Intervention: Human observer
Number of subjects: 0
Study 15669610 — intervention group
Group type: COMPARATOR
Intervention: Ideal observer
Number of subjects: 0
Study 16051958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 710
Study 16051958 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 710
Study 10840409 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 90
Study 10840409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated surgically)
Number of subjects: 90
Study 9101613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (Child A and B)
Number of subjects: 30
Study 9101613 — intervention group
Group type: EXPERIMENTAL
Intervention: Child B patients
Number of subjects: 30
Study 9101613 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 30
Study 8222658 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing gestodene
Number of subjects: 0
Study 8222658 — intervention group
Group type: COMPARATOR
Intervention: Triphasic oral contraceptive containing norethindrone
Number of subjects: 0
Study 3467701 — intervention group
Group type: EXPERIMENTAL
Intervention: High calorie and protein clear fluid regime
Number of subjects: 16
Study 3467701 — intervention group
Group type: COMPARATOR
Intervention: Standard clear fluids
Number of subjects: 16
Study 3397253 — intervention group
Group type: EXPERIMENTAL
Intervention: rosaprostol
Number of subjects: 18
Study 3397253 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 30125457 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n‐3 fatty acids (2.6 g daily for 44 weeks)
Number of subjects: 132
Study 28479622 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic support (conditional cash transfers up to 230 USD, community meetings, household visits)
Number of subjects: 312
Study 28479622 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus socioeconomic support
Number of subjects: 312
Study 28479622 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 312
Study 25311952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 75
Study 23351923 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-finished occlusal appliance (SB)
Number of subjects: 63
Study 23351923 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-made occlusal appliance (SS)
Number of subjects: 63
Study 23351923 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (CO)
Number of subjects: 63
Study 23351923 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-finished occlusal appliance (SB) and Laboratory-made occlusal appliance (SS)
Number of subjects: 63
Study 21733177 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, low fat diet
Number of subjects: 370
Study 21733177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate, high fat diet
Number of subjects: 370
Study 21733177 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention control group
Number of subjects: 370
Study 19287306 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH 1500 mg/m before oxaliplatin infusion
Number of subjects: 27
Study 19287306 — intervention group
Group type: COMPARATOR
Intervention: Saline solution before oxaliplatin infusion (Control)
Number of subjects: 27
Study 16704986 — intervention group
Group type: EXPERIMENTAL
Intervention: Brassica Vegetable (BV) intervention
Number of subjects: 20
Study 16704986 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient and Fiber Supplementation (M+F) intervention
Number of subjects: 20
Study 11812711 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection with 8 mL of 0.125% bupivacaine and 40 mg of methylprednisolone (20 mg/mL) at a rate of 6 mL/min.
Number of subjects: 23
Study 11812711 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion pressure measurement in DSD patients before treatment.
Number of subjects: 23
Study 11812711 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with no history of back pain).
Number of subjects: 23
Study 10075339 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced consumption of saturated fat and cholesterol (Intervention group, n = 540)
Number of subjects: 730
Study 10075339 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 522)
Number of subjects: 730
Study 7555530 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (mean daily dose 35 +/- 11.4 mg)
Number of subjects: 102
Study 7555530 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (mean daily dose 50 +/- 12.9 mg)
Number of subjects: 102
Study 7555530 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 102
Study 7555530 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 102
Study 2340615 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 42
Study 2340615 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 42
Study 2340615 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta-blockers)
Number of subjects: 42
Study 7371971 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper Pill (30 microgram ethinyloestradiol and 150 microgram levonorgestrel)
Number of subjects: 336
Study 7371971 — intervention group
Group type: COMPARATOR
Intervention: Microgynon 30 (conventional tablet formulation)
Number of subjects: 336
Study 29689057 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS) intervention
Number of subjects: 1419
Study 29689057 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MN) supplementation
Number of subjects: 1419
Study 29689057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PS and MN
Number of subjects: 1419
Study 28844318 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (1 to 24 development units, DU)
Number of subjects: 70
Study 28844318 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (12 and 24 DU)
Number of subjects: 70
Study 28844318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25679135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 14
Study 25679135 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study 24047236 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (Staff as Change Agents - Enhancing and Sustaining Mental Health in Aged Care)
Number of subjects: 18
Study 24047236 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program and clinical support
Number of subjects: 18
Study 24047236 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 18
Study 21357377 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere length in peripheral blood leukocytes (longest quartile vs. shortest quartile)
Number of subjects: 3108
Study 21357377 — intervention group
Group type: COMPARATOR
Intervention: Telomere length in peripheral blood leukocytes
Number of subjects: 3108
Study 18705795 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVA
Number of subjects: 0
Study 18705795 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample t-test
Number of subjects: 0
Study 18705795 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomized studies
Number of subjects: 0
Study 17557435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 4 mg
Number of subjects: 232
Study 17557435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 6 mg
Number of subjects: 232
Study 17557435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 8 mg
Number of subjects: 232
Study 17557435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 10 mg
Number of subjects: 232
Study 17557435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 15058157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication (0.15 mg)
Number of subjects: 102
Study 15058157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine premedication (0.15 mg)
Number of subjects: 102
Study 15058157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral or intramuscular)
Number of subjects: 102
Study 15058157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intramuscular clonidine
Number of subjects: 102
Study 15058157 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 102
Study 15058157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine
Number of subjects: 102
Study 11011346 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/d for 8 weeks
Number of subjects: 38
Study 11011346 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/d plus Enalapril 5 mg/d for 8 weeks
Number of subjects: 38
Study 11011346 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/d for 8 weeks
Number of subjects: 38
Study 11011346 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/d plus Simvastatin 10 mg/d for 8 weeks
Number of subjects: 38
Study 11011346 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (control)
Number of subjects: 38
Study 8800119 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg/day oral propafenone (Group 1)
Number of subjects: 47
Study 1792326 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique of set-up with fixed arm support (group 2)
Number of subjects: 14
Study 1792326 — intervention group
Group type: COMPARATOR
Intervention: Technique of set-up without fixed arm support (group 1)
Number of subjects: 14
Study 6407305 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole prophylaxis
Number of subjects: 47
Study 31594876 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily for 1 month, followed by 80 mg daily for 23 months)
Number of subjects: 235
Study 31594876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched to simvastatin)
Number of subjects: 235
Study 29866583 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography plus standard care
Number of subjects: 273
Study 29866583 — intervention group
Group type: COMPARATOR
Intervention: Standard care without point-of-care ultrasonography
Number of subjects: 273
Study 29866583 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography plus standard care (North America)
Number of subjects: 273
Study 29866583 — intervention group
Group type: COMPARATOR
Intervention: Standard care without point-of-care ultrasonography (North America)
Number of subjects: 273
Study 29866583 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography plus standard care (South Africa)
Number of subjects: 273
Study 29866583 — intervention group
Group type: COMPARATOR
Intervention: Standard care without point-of-care ultrasonography (South Africa)
Number of subjects: 273
Study 27665091 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 54
Study 27665091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 24030863 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI with bivalirudin, with or without intralesion abciximab and thrombus aspiration
Number of subjects: 451
Study 24261227 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptol 1500-2000 mg/day for 30+2 days
Number of subjects: 94
Study 24261227 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only (Control)
Number of subjects: 94
Study 20129356 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO(2) preconditioning for two 30-min intervals at 2.4 ATA
Number of subjects: 81
Study 20129356 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO(2) preconditioning
Number of subjects: 81
Study 18392690 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/day; n = 14)
Number of subjects: 35
Study 18392690 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day; n = 11)
Number of subjects: 35
Study 18392690 — intervention group
Group type: COMPARATOR
Intervention: placebo (medical nutrition therapy; n = 10)
Number of subjects: 35
Study 18392690 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 35
Study 15945501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide (pre-IB)
Number of subjects: 16
Study 15945501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide (post-IB)
Number of subjects: 16
Study 15945501 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 16
Study 12837435 — intervention group
Group type: EXPERIMENTAL
Intervention: tadalafil 20 mg
Number of subjects: 348
Study 12837435 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 348
Study 10440425 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily for 7 days
Number of subjects: 22
Study 10440425 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 7 days
Number of subjects: 22
Study 10440425 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 22
Study 10440425 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta-blocker)
Number of subjects: 22
Study 10440425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (calcium uptake antagonist)
Number of subjects: 22
Study 10440425 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 22
Study 8646251 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF) 30 mg/day
Number of subjects: 29
Study 8646251 — intervention group
Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 29
Study 8646251 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 29
Study 1349486 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release verapamil 200 mg b.i.d.
Number of subjects: 20
Study 1349486 — intervention group
Group type: EXPERIMENTAL
Intervention: conventional verapamil 120 mg t.i.d.
Number of subjects: 20
Study 1349486 — intervention group
Group type: COMPARATOR
Intervention: beta-blockade and long-acting nitrates
Number of subjects: 20
Study 3972657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rate radiotherapy
Number of subjects: 48
Study 3972657 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated irradiation at normal high dose rate
Number of subjects: 48
Study 31181022 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy device (cold and vibration)
Number of subjects: 607
Study 31181022 — intervention group
Group type: COMPARATOR
Intervention: EMLA patch (standard care)
Number of subjects: 607
Study 31765604 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Number of subjects: 690
Study 31765604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study 28950725 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (12-week program, 30 min/day)
Number of subjects: 241
Study 28950725 — intervention group
Group type: COMPARATOR
Intervention: Comparison health and wellness intervention
Number of subjects: 241